GlassScriptPhysician profile
Anthony R Lambert
NPI 1982691218
$4,103.06
in general payments reported to CMS, 2019-2025
30 companies · $764 in 2025
The $764 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $977 · 2022: $905 · 2023: $881 · 2024: $576 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,477.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $546.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $266.16 | 2021-2025 | |
| Pfizer INC. | $246.96 | 2021-2025 | |
| Medtronic, INC. | $176.25 | 2023 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $125.64 | 2021-2022 | |
| Exact Sciences Corporation | $122.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.54 | 2021-2025 | Xifaxan, Trulance |
| Grifols USA, LLC | $119.12 | 2021-2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $100.21 | 2022-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $75.47 | 2021-2024 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $72.34 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $63.35 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $57.91 | 2021-2025 | Veozah |
| Abbott Laboratories | $56.70 | 2022-2023 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.20 | 2021-2025 | Rexulti |
| Biogen, INC. | $46.62 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.30 | 2024-2025 | Caplyta |
| Amgen INC. | $43.80 | 2021-2022 | |
| Radius Health, INC. | $34.27 | 2023 | |
| Boston Scientific Corporation | $32.35 | 2022-2024 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Dexcom, INC. | $26.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.71 | 2023 | |
| Axsome Therapeutics, INC. | $23.59 | 2025 | Auvelity |
| Lundbeck LLC | $21.65 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.38 | 2023 | Fasenra |
| Phathom Pharmaceuticals, INC. | $16.12 | 2025 | Voquezna |
| Eisai INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.